Tenaya Therapeutics

Edit info

Founded: 2016

Location: South SF, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Heart failure with preserved ejection fraction

Drug types: CVV, GEN

Lead product: TN-301

Funding: $75M stock Nov 2022; $207M IPO Jul 2021; $106M C Mar 2021; $92M Oct 2019; $50M A Dec 2016

tenayatherapeutics.com

linkedin.com

job board

Drug notes:

TN-201 Clin0 genetic hypertrophic cardiomyopathy (FT); TN-401 Clin0 genetic arrhythmogenic right ventricular cardiomyopathy; 4 undisclosed programs RD/Clin0 dilated cardiomyopathy, heart failures, genetic conditions, undisclosed

About:

Tenaya Therapeutics is discovering and developing therapies for patients with heart diseases. Conditions affecting the heart affect individuals of all ages in a variety of ways. Tenaya is pursuing three distinct platforms to revolutionize heart disease treatment: gene therapy to restore cell function by delivering healthy copies of genes, cellular regeneration to regenerate new heart cells in vivo that are lost due to a heart attack, and precision medicine to identify new targets that can be used for novel therapies. With these platforms, Tenaya is creating a deep and diverse pipeline of therapeutic programs intended for rare and prevalent heart diseases.

Jobs:

Main

Contact: recruit@workinbiotech.com